-
1
-
-
0027320440
-
Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
-
Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, Ter Schegget J, Melief CJ, Kast WM. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-2249
-
(1993)
Eur J Immunol
, vol.23
, pp. 2242-2249
-
-
Feltkamp, M.C.1
Smits, H.L.2
Vierboom, M.P.3
Minnaar, R.P.4
De Jongh, B.M.5
Drijfhout, J.W.6
Ter Schegget, J.7
Melief, C.J.8
Kast, W.M.9
-
2
-
-
0035163903
-
Combined allogeneic tumor cell vaccination and systematic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice
-
DOI 10.1084/jem.194.9.1195
-
Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 2001;194:1195-1205 (Pubitemid 33055039)
-
(2001)
Journal of Experimental Medicine
, vol.194
, Issue.9
, pp. 1195-1205
-
-
Nanni, P.1
Nicoletti, G.2
De Giovanni, C.3
Landuzzi, L.4
Di Carlo, E.5
Cavallo, F.6
Pupa, S.M.7
Rossi, I.8
Colombo, M.P.9
Ricci, C.10
Astolfi, A.11
Musiani, P.12
Forni, G.13
Lollini, P.-L.14
-
3
-
-
33748987908
-
Cancer despite immunosurveillance: Immunoselection and immunosubversion
-
Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006;6:715-727
-
(2006)
Nat Rev Immunol
, vol.6
, pp. 715-727
-
-
Zitvogel, L.1
Tesniere, A.2
Kroemer, G.3
-
4
-
-
0031091743
-
Is CTLA-4 a master switch for peripheral T cell tolerance?
-
Bluestone JA. Is CTLA-4 a master switch for peripheral T cell tolerance? J Immunol 1997;158:1989-1993
-
(1997)
J Immunol
, vol.158
, pp. 1989-1993
-
-
Bluestone, J.A.1
-
5
-
-
0034679567
-
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+) CD4(+) regulatory cells that control intestinal inflammation
-
Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+) CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295-302.
-
(2000)
J Exp Med
, vol.192
, pp. 295-302
-
-
Read, S.1
Malmstrom, V.2
Powrie, F.3
-
6
-
-
33749132564
-
Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo
-
Read S, Greenwald R, Izcue A, Robinson N, Mandelbrot D, Francisco L et al. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol 2006;177:4376-4383
-
(2006)
J Immunol
, vol.177
, pp. 4376-4383
-
-
Read, S.1
Greenwald, R.2
Izcue, A.3
Robinson, N.4
Mandelbrot, D.5
Francisco, L.6
-
7
-
-
49649113444
-
Acquisition of suppressive function by activated human CD4+ CD25- T cells is associated with the expression of CTLA-4 not FoxP3
-
Zheng Y, Manzotti CN, Burke F, Dussably L, Qureshi O, Walker LS et al. Acquisition of suppressive function by activated human CD4+ CD25- T cells is associated with the expression of CTLA-4 not FoxP3. J Immunol 2008;181:1683-1691
-
(2008)
J Immunol
, vol.181
, pp. 1683-1691
-
-
Zheng, Y.1
Manzotti, C.N.2
Burke, F.3
Dussably, L.4
Qureshi, O.5
Walker, L.S.6
-
8
-
-
0033168037
-
Tumor rejection by in vivo administration of anti-CD25 (interleukin- 2 receptor alpha) monoclonal antibody
-
Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin- 2 receptor alpha) monoclonal antibody. Cancer Res 1999;59:3128-3133
-
(1999)
Cancer Res
, vol.59
, pp. 3128-3133
-
-
Onizuka, S.1
Tawara, I.2
Shimizu, J.3
Sakaguchi, S.4
Fujita, T.5
Nakayama, E.6
-
9
-
-
0029947568
-
Enhancement of antitumor immunity by CTLA-4 blockade
-
Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-1736
-
(1996)
Science
, vol.271
, pp. 1734-1736
-
-
Leach, D.R.1
Krummel, M.F.2
Allison, J.P.3
-
10
-
-
0025320534
-
Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes -a molecule related to nerve growth factor receptor
-
Mallett S, Fossum S, Barclay AN. Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes -a molecule related to nerve growth factor receptor. Embo J 1990;9:1063-1068
-
(1990)
Embo J
, vol.9
, pp. 1063-1068
-
-
Mallett, S.1
Fossum, S.2
Barclay, A.N.3
-
11
-
-
0029812623
-
OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand
-
al-Shamkhani A, Birkeland ML, Puklavec M, Brown MH, James W, Barclay AN. OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand. Eur J Immunol 1996;26:1695-1699
-
(1996)
Eur J Immunol
, vol.26
, pp. 1695-1699
-
-
Al-Shamkhani, A.1
Birkeland, M.L.2
Puklavec, M.3
Brown, M.H.4
James, W.5
Barclay, A.N.6
-
12
-
-
0034306979
-
Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth
-
Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, Shu S. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res 2000;60:5514-5521
-
(2000)
Cancer Res
, vol.60
, pp. 5514-5521
-
-
Kjaergaard, J.1
Tanaka, J.2
Kim, J.A.3
Rothchild, K.4
Weinberg, A.5
Shu, S.6
-
13
-
-
0028484545
-
CTLA-4 can function as a negative regulator of T cell activation
-
Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-413
-
(1994)
Immunity
, vol.1
, pp. 405-413
-
-
Walunas, T.L.1
Lenschow, D.J.2
Bakker, C.Y.3
Linsley, P.S.4
Freeman, G.J.5
Green, J.M.6
-
14
-
-
0017661198
-
Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: Description of a unique antigen on BALB/c Meth A sarcoma
-
DeLeo AB, Shiku H, Takahashi T, John M, Old LJ. Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma. J Exp Med 1977;146:720-734
-
(1977)
J Exp Med
, vol.146
, pp. 720-734
-
-
Deleo, A.B.1
Shiku, H.2
Takahashi, T.3
John, M.4
Old, L.J.5
-
15
-
-
34248350754
-
Spleen plays an important role in maintaining tolerance after removal of the vascularized heart graft
-
Chosa E, Hara M, Watanabe A, Matsuzaki Y, Nakamura K, Hamano K et al. Spleen plays an important role in maintaining tolerance after removal of the vascularized heart graft. Transplantation 2007;83:1226-1233
-
(2007)
Transplantation
, vol.83
, pp. 1226-1233
-
-
Chosa, E.1
Hara, M.2
Watanabe, A.3
Matsuzaki, Y.4
Nakamura, K.5
Hamano, K.6
-
17
-
-
34047220868
-
Cancer immunoediting from immune surveillance to immune escape
-
Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007;121:1-14.
-
(2007)
Immunology
, vol.121
, pp. 1-14
-
-
Kim, R.1
Emi, M.2
Tanabe, K.3
-
18
-
-
33244472107
-
Tumor-infiltrating T lymphocytes: Friends or foes?
-
Yu P, Fu YX. Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest 2006;86:231-245
-
(2006)
Lab Invest
, vol.86
, pp. 231-245
-
-
Yu, P.1
Fu, Y.X.2
-
19
-
-
4644237613
-
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
-
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949
-
(2004)
Nat Med
, vol.10
, pp. 942-949
-
-
Curiel, T.J.1
Coukos, G.2
Zou, L.3
Alvarez, X.4
Cheng, P.5
Mottram, P.6
-
20
-
-
0029783148
-
Protective antitumor immunity induced by immunization with completely allogeneic tumor cells
-
Toes RE, Blom RJ, van der Voort E, Offringa R, Melief CJ, Kast WM. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res 1996;56:3782-3787
-
(1996)
Cancer Res
, vol.56
, pp. 3782-3787
-
-
Toes, R.E.1
Blom, R.J.2
Van Der Voort, E.3
Offringa, R.4
Melief, C.J.5
Kast, W.M.6
-
21
-
-
0031758085
-
Peptide vaccination with an anchorreplaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope
-
Vierboom MP, Feltkamp MC, Neisig A, Drijfhout JW, ter Schegget J, Neefjes JJ et al. Peptide vaccination with an anchorreplaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope. J Immunother 1998;21:399-408.
-
(1998)
J Immunother
, vol.21
, pp. 399-408
-
-
Vierboom, M.P.1
Feltkamp, M.C.2
Neisig, A.3
Drijfhout, J.W.4
Ter Schegget, J.5
Neefjes, J.J.6
-
22
-
-
14844334891
-
Breaking tolerance in cancer immunotherapy: Time to ACT
-
Overwijk WW. Breaking tolerance in cancer immunotherapy: time to ACT. Curr Opin Immunol 2005;17:187-194
-
(2005)
Curr Opin Immunol
, vol.17
, pp. 187-194
-
-
Overwijk, W.W.1
-
23
-
-
1642390941
-
Activation requirements for the induction of CD4+CD25+ T cell suppressor function
-
Thornton AM, Piccirillo CA, Shevach EM. Activation requirements for the induction of CD4+CD25+ T cell suppressor function. Eur J Immunol 2004;34:366-376
-
(2004)
Eur J Immunol
, vol.34
, pp. 366-376
-
-
Thornton, A.M.1
Piccirillo, C.A.2
Shevach, E.M.3
-
24
-
-
0035421654
-
Cutting edge: Control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells
-
Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001;167:1137-1140
-
(2001)
J Immunol
, vol.167
, pp. 1137-1140
-
-
Piccirillo, C.A.1
Shevach, E.M.2
-
25
-
-
0033563271
-
CTLA-4-Mediated inhibition of early events of T cell proliferation
-
Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol 1999;162:5813-5820
-
(1999)
J Immunol
, vol.162
, pp. 5813-5820
-
-
Brunner, M.C.1
Chambers, C.A.2
Chan, F.K.3
Hanke, J.4
Winoto, A.5
Allison, J.P.6
-
26
-
-
0035892897
-
Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/memory development and humoral immunity: Comparison of alphaOX-40 with alphaCTLA-4
-
Evans DE, Prell RA, Thalhofer CJ, Hurwitz AA, Weinberg AD. Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4. J Immunol 2001;167:6804-6811
-
(2001)
J Immunol
, vol.167
, pp. 6804-6811
-
-
Evans, D.E.1
Prell, R.A.2
Thalhofer, C.J.3
Hurwitz, A.A.4
Weinberg, A.D.5
-
27
-
-
0032534582
-
Ox-40 ligand: A potent costimulatory molecule for sustaining primary CD4 T cell responses
-
Gramaglia I, Weinberg AD, Lemon M, Croft M. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 1998;161:6510-6517
-
(1998)
J Immunol
, vol.161
, pp. 6510-6517
-
-
Gramaglia, I.1
Weinberg, A.D.2
Lemon, M.3
Croft, M.4
-
28
-
-
33646356996
-
Adoptive immunotherapy for cancer: Building on success
-
Gattinoni L, Powell DJ, Jr., Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006;6:383-393
-
(2006)
Nat Rev Immunol
, vol.6
, pp. 383-393
-
-
Gattinoni, L.1
Powell Jr., D.J.2
Rosenberg, S.A.3
Restifo, N.P.4
-
29
-
-
0348223787
-
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3
-
Chen W, Jin W, Hardegen N, Lei KJ, Li L; Marinos N et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003;198:1875-1886
-
(2003)
J Exp Med
, vol.198
, pp. 1875-1886
-
-
Chen, W.1
Jin, W.2
Hardegen, N.3
Lei, K.J.4
Li, L.5
Marinos, N.6
-
31
-
-
0036597371
-
CD4+ CD25+ suppressor T cells: More questions than answers
-
Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389-400.
-
(2002)
Nat Rev Immunol
, vol.2
, pp. 389-400
-
-
Shevach, E.M.1
-
32
-
-
9244261022
-
Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function
-
Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone JA. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol 2004;34:2996-3005.
-
(2004)
Eur J Immunol
, vol.34
, pp. 2996-3005
-
-
Tang, Q.1
Boden, E.K.2
Henriksen, K.J.3
Bour-Jordan, H.4
Bi, M.5
Bluestone, J.A.6
-
33
-
-
0036467522
-
CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10- dependent immunoregulation of alloresponses
-
Kingsley CI, Karim M, Bushell AR, Wood KJ. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10- dependent immunoregulation of alloresponses. J Immunol 2002;168:1080-1086
-
(2002)
J Immunol
, vol.168
, pp. 1080-1086
-
-
Kingsley, C.I.1
Karim, M.2
Bushell, A.R.3
Wood, K.J.4
-
34
-
-
0022473607
-
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
-
Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233:1318-1321
-
(1986)
Science
, vol.233
, pp. 1318-1321
-
-
Rosenberg, S.A.1
Spiess, P.2
Lafreniere, R.3
-
35
-
-
0020047427
-
Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells
-
North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982;155:1063-1074
-
(1982)
J Exp Med
, vol.155
, pp. 1063-1074
-
-
North, R.J.1
-
36
-
-
55949125601
-
Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens
-
Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26:5233-5239
-
(2008)
J Clin Oncol
, vol.26
, pp. 5233-5239
-
-
Dudley, M.E.1
Yang, J.C.2
Sherry, R.3
Hughes, M.S.4
Royal, R.5
Kammula, U.6
-
38
-
-
3142782785
-
Recombinant immunotoxins for the treatment of haematological malignancies
-
Kreitman RJ. Recombinant immunotoxins for the treatment of haematological malignancies. Expert Opin Biol Ther 2004;4:1115-1128
-
(2004)
Expert Opin Biol Ther
, vol.4
, pp. 1115-1128
-
-
Kreitman, R.J.1
-
39
-
-
0035903324
-
Synergism of cytotoxic T lymphocyte- associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses
-
Sutmuller RP. van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP et al. Synergism of cytotoxic T lymphocyte- associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001;194:823-832
-
(2001)
J Exp Med
, vol.194
, pp. 823-832
-
-
Sutmuller, R.P.1
Van Duivenvoorde, L.M.2
Van Elsas, A.3
Schumacher, T.N.4
Wildenberg, M.E.5
Allison, J.P.6
|